CRSP COO Julianne Bruno steps down effective April 11, 2025

CRISPR Therapeutics AG

Julianne Bruno resigns as COO of CRISPR Therapeutics to pursue external opportunities.
Departure effective April 11, 2025; she remains an employee until that date.
Resignation not the result of any disagreement with the company.
CEO Samarth Kulkarni thanked Bruno for six years of leadership in hematology and oncology.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Julianne Bruno

Chief Operating Officer

CRSP · CRISPR Therapeutics AG

Effective: 2025-04-11
Filed: March 26, 2025, 7:59 PM ET

On March 24, 2025, Julianne Bruno informed CRISPR Therapeutics AG (the “Company”) that she would be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025, and she resigned from her position as Chief Operating Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Julianne Bruno resigned as Chief Operating Officer at CRISPR Therapeutics AG.

Action: resigned
Role: Chief Operating Officer

Exact text from the filing

On March 24, 2025, Julianne Bruno informed CRISPR Therapeutics AG (the “Company”) that she would be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025, and she resigned from her position as Chief Operating Officer of the Company.

View on SEC.gov

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-25-045232

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.